AIM: Liver fibrosis is a common pathological process of chronic liver diseases. Activation of hepatic stellate cells(HSCs) is the key issue in the occurrence of liver fibrosis. In this study, we observed the inhibitor...AIM: Liver fibrosis is a common pathological process of chronic liver diseases. Activation of hepatic stellate cells(HSCs) is the key issue in the occurrence of liver fibrosis. In this study, we observed the inhibitory action of rat serum containing Biejiajian oral liquid (BOL), a decoction of turtle shell, on proliferation of rat HSCs, and to explore the antihepatofibrotic mechanisms of BOL.METHODS: A rat model of hepatic fibrosis was induced by subcutaneous injection of CC14. Serum containing low,medium and high dosages of BOL was prepared respectively.Normal and fibrotic HSCs were isolated and cultured. The effect of sera containing BOL on proliferation of HSCs was determined by 3H-TdR incorporation.RESULTS: The inhibitory rate of normal rat HSC proliferation caused by 100 mL/mL sera containing medium and high dosages of BOL showed a remarkable difference as compared with that caused by colchicine (medium dosage group:34.56±4.21% vs29.12±2.85%, P<0.01; high dosage group:37.82±1.32% vs29.12±2.85%, P<0.01). The inhibitory rate of fibrotic rat HSC proliferation caused by 100 mL/L serum containing medium and high dosages of BOL showed a remarkable difference as compared with that caused by colchicine (medium dosage group: 51.31_+3.14% vs 38.32_+2.65%,P<0.01; high dosage group: 60.15_+5.36% vs38.32_+2.65%,P<0.01). The inhibitory rate of normal rat HSC proliferation caused by 100 mL/L and 200 mL/L sera containing a medium dosage of BOL showed a significant difference as compared with that caused by 50 mL/L (100 mL/L group: 69.02±9.96%vs 50.82±9.28%, P<0.05; 200 mL/L group: 81.78±8.92%vs50.82±9.28%, P<0.01). The inhibitory rate of fibrotic rat HSC proliferation caused by 100 mL/L and 200 mL/L sera containing a medium dosage of BOL showed a significant difference as compared with that caused by 50 mL/L (100 mL/L group:72.19±10.96% vs 61.38±7.16%, P<0.05; 200 mL/L group:87.16±8.54% vs 61.38±7.16%, P<0.01).CONCLUSION: Rat serum containing BOL can inhibit proliferation of rat HSCs, and the inhibition depends on the dosage and concentration of BOL. The inhibitory effect on HSC proliferation is one of the main anti-hepatofibroticmechanisms of BOL.展开更多
In the past decade,an increased amount of clinicallyloriented research involving immunotoxins has been published. Immunotoxins are a group of artificially-made cytotoxic molecules targeting cancer cells.These molecule...In the past decade,an increased amount of clinicallyloriented research involving immunotoxins has been published. Immunotoxins are a group of artificially-made cytotoxic molecules targeting cancer cells.These molecules composed of a targeting moiety,such as a ligand or an antibody,linked to toxin moiety,which is a toxin with either truncated or deleted cell-binding domain that prevents it from binding to normal cells.Immunotoxins can be divided into two categories:chemically conjugated immunotoxins and recombinant ones.The immunotoxins of the first category have shown limited efficacy in clinical trials in patients with hematologic malignancies and solid tumors.Within the last few years,single-chain immunotoxins provide enhanced therapeutic efficacy over conjugated forms and result in improved antitumor activity.In this review,we briefly illustrate the design of the immunotoxins and their applications in clinical trials.Cellular & Molecular Immunology.2005;2(2):106-112.展开更多
基金Supported by the Natural Science Foundation of Zhejiang Province,No.398402
文摘AIM: Liver fibrosis is a common pathological process of chronic liver diseases. Activation of hepatic stellate cells(HSCs) is the key issue in the occurrence of liver fibrosis. In this study, we observed the inhibitory action of rat serum containing Biejiajian oral liquid (BOL), a decoction of turtle shell, on proliferation of rat HSCs, and to explore the antihepatofibrotic mechanisms of BOL.METHODS: A rat model of hepatic fibrosis was induced by subcutaneous injection of CC14. Serum containing low,medium and high dosages of BOL was prepared respectively.Normal and fibrotic HSCs were isolated and cultured. The effect of sera containing BOL on proliferation of HSCs was determined by 3H-TdR incorporation.RESULTS: The inhibitory rate of normal rat HSC proliferation caused by 100 mL/mL sera containing medium and high dosages of BOL showed a remarkable difference as compared with that caused by colchicine (medium dosage group:34.56±4.21% vs29.12±2.85%, P<0.01; high dosage group:37.82±1.32% vs29.12±2.85%, P<0.01). The inhibitory rate of fibrotic rat HSC proliferation caused by 100 mL/L serum containing medium and high dosages of BOL showed a remarkable difference as compared with that caused by colchicine (medium dosage group: 51.31_+3.14% vs 38.32_+2.65%,P<0.01; high dosage group: 60.15_+5.36% vs38.32_+2.65%,P<0.01). The inhibitory rate of normal rat HSC proliferation caused by 100 mL/L and 200 mL/L sera containing a medium dosage of BOL showed a significant difference as compared with that caused by 50 mL/L (100 mL/L group: 69.02±9.96%vs 50.82±9.28%, P<0.05; 200 mL/L group: 81.78±8.92%vs50.82±9.28%, P<0.01). The inhibitory rate of fibrotic rat HSC proliferation caused by 100 mL/L and 200 mL/L sera containing a medium dosage of BOL showed a significant difference as compared with that caused by 50 mL/L (100 mL/L group:72.19±10.96% vs 61.38±7.16%, P<0.05; 200 mL/L group:87.16±8.54% vs 61.38±7.16%, P<0.01).CONCLUSION: Rat serum containing BOL can inhibit proliferation of rat HSCs, and the inhibition depends on the dosage and concentration of BOL. The inhibitory effect on HSC proliferation is one of the main anti-hepatofibroticmechanisms of BOL.
文摘In the past decade,an increased amount of clinicallyloriented research involving immunotoxins has been published. Immunotoxins are a group of artificially-made cytotoxic molecules targeting cancer cells.These molecules composed of a targeting moiety,such as a ligand or an antibody,linked to toxin moiety,which is a toxin with either truncated or deleted cell-binding domain that prevents it from binding to normal cells.Immunotoxins can be divided into two categories:chemically conjugated immunotoxins and recombinant ones.The immunotoxins of the first category have shown limited efficacy in clinical trials in patients with hematologic malignancies and solid tumors.Within the last few years,single-chain immunotoxins provide enhanced therapeutic efficacy over conjugated forms and result in improved antitumor activity.In this review,we briefly illustrate the design of the immunotoxins and their applications in clinical trials.Cellular & Molecular Immunology.2005;2(2):106-112.
